Maintenance Galinpepimut-S Appears Effective and Safe in AML in Second CR
Galinpepimut-S demonstrated early efficacy signals in patients with acute myeloid leukemia in second complete remission or later.
Related Articles
Liso-cel Demonstrates Significant Responses in Relapsed/Refractory MZL
In the phase 2 TRANSCEND FL trial, lisocabtagene maraleucel met its primary end point of overall response rate in patients with marginal zone lymphoma.
Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III–IVa cervical cancer: is the ENGOT‐cx11/GOG‐3047/KEYNOTE‐A18 trial practice changing?
The ENGOT-cx11/GOG-3047/KEYNOTE-A18 randomized controlled trial demonstrated an overall survival benefit in cervical cancer patients treated with pembrolizumab during and after chemoradiotherapy as c…
First-of-Its-Kind Supportive Oncology Program Offers Unique Training Opportunity for Fellows
The Christie NHS Foundation Trust has created a supportive oncology program to train fellows and offer services for patients living with cancer.
Classification of non-TCGA cancer samples to TCGA molecular subtypes using compact feature sets
Ellrott et al. provide a means to assign patient samples from clinical trials and other cancer genome studies to published TCGA molecular subtypes. Applying machine learning…
MajesTEC-5 Latest data: Teclistamab-DR ± bortezomib for TE-NDMM
MajesTEC-5 is a phase II trial evaluating teclistamab in combination with DR, with or without bortezomib, for NDMM. During ASH 2024, Marc Raab presented initial…
Radiation-induced cardiac disease: Modern techniques to reduce cardiac toxicity
Continuous advancements in cancer management have resulted in increased long-term survival rates amongst cancer survivors and in turn have exposed the full extent of radiotherapy-associated…
Elacestrant Shows Greater Benefit in Endocrine-Sensitive Breast Cancer
Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1…
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
Sacituzumab govitecan (SG), a Trop-2-directed antibody–drug conjugate, demonstrated efficacy and manageable toxicity in the phase II TROPHY-U-01 study in pretreated advanced urothelial carcinoma (aUC). We…
Pertuzumab Retreatment in HER2-Positive Locally Advanced/Metastatic Breast Cancer
As reported in the Journal of Clinical Oncology by Yamamoto et al, the final overall survival analysis of the Japanese phase III PRECIOUS study showed…
Trump administration caps indirect costs at 15%, inviting injunctions, congressional scrutiny The move could gut academic cancer research – The Cancer Letter
Late on Friday, Feb. 7, the Trump administration announced that indirect costs paid on grants to U.S. medical research institutions would—starting immediately—henceforth be capped at…
